Should anti-diabetic medications be reconsidered amid COVID-19 pandemic?
作者信息
Pal Rimesh, Bhadada Sanjay K
机构信息
Department of Endocrinology, Post Graduate Institute of Medical Education and Research, Chandigarh 160012, India.
Department of Endocrinology, Post Graduate Institute of Medical Education and Research, Chandigarh 160012, India.
出版信息
Diabetes Res Clin Pract. 2020 May;163:108146. doi: 10.1016/j.diabres.2020.108146. Epub 2020 Apr 10.
Abstract
摘要
相似文献
1
Should anti-diabetic medications be reconsidered amid COVID-19 pandemic?在新冠疫情期间是否应重新考虑抗糖尿病药物？
Diabetes Res Clin Pract. 2020 May;163:108146. doi: 10.1016/j.diabres.2020.108146. Epub 2020 Apr 10.
2
Comment on "Should anti-diabetic medications be reconsidered amid COVID-19 pandemic?".关于《在2019冠状病毒病大流行期间是否应重新考虑抗糖尿病药物？》的评论
Diabetes Res Clin Pract. 2020 Jun;164:108184. doi: 10.1016/j.diabres.2020.108184. Epub 2020 Apr 30.
3
Reply to comment on "Should anti-diabetic medications be reconsidered amid COVID-19 pandemic?".对“在2019冠状病毒病大流行期间是否应重新考虑抗糖尿病药物？”一文评论的回复
Diabetes Res Clin Pract. 2020 Jun;164:108192. doi: 10.1016/j.diabres.2020.108192. Epub 2020 May 6.
4
Investigation of angiotensin-1 converting enzyme 2 gene (G8790A) polymorphism in patients of type 2 diabetes mellitus with diabetic nephropathy in Pakistani population.探讨巴基斯坦 2 型糖尿病合并糖尿病肾病患者血管紧张素转化酶 2 基因（G8790A）多态性。
PLoS One. 2022 Feb 17;17(2):e0264038. doi: 10.1371/journal.pone.0264038. eCollection 2022.
5
COVID-19 and Type 2 Diabetes Mellitus: HCQ may be the Holy Grail.COVID-19 与 2 型糖尿病：羟氯喹可能是圣杯。
Infect Disord Drug Targets. 2021;21(5):e270421186842. doi: 10.2174/1871526520666201013160803.
6
Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.血管紧张素转换酶 2 和肾素血管紧张素系统抑制剂在 COVID-19 中的应用：最新进展。
High Blood Press Cardiovasc Prev. 2021 Mar;28(2):129-139. doi: 10.1007/s40292-021-00439-9. Epub 2021 Feb 26.
7
Glycated ACE2 reduces anti-remodeling effects of renin-angiotensin system inhibition in human diabetic hearts.糖基化 ACE2 降低了肾素-血管紧张素系统抑制在人类糖尿病心脏中的抗重构作用。
Cardiovasc Diabetol. 2022 Aug 5;21(1):146. doi: 10.1186/s12933-022-01573-x.
8
Expression of the SARS-CoV-2 receptorACE2 in human heart is associated with uncontrolled diabetes, obesity, and activation of the renin angiotensin system.SARS-CoV-2 受体 ACE2 在人心脏中的表达与不受控制的糖尿病、肥胖症以及肾素血管紧张素系统的激活有关。
Cardiovasc Diabetol. 2021 Apr 27;20(1):90. doi: 10.1186/s12933-021-01275-w.
9
Comparison of Diabetic Ketoacidosis Characteristics During- and Before the COVID-19 Pandemic.2019年冠状病毒病大流行期间与大流行之前糖尿病酮症酸中毒特征的比较
Int J Endocrinol Metab. 2023 Jun 18;21(3):e134882. doi: 10.5812/ijem-134882. eCollection 2023 Jul.
10
Temporal trends in optimal diabetic care and complications of elderly type 2 diabetes patients in Thailand: A nationwide study.泰国老年 2 型糖尿病患者最佳糖尿病护理及并发症的时间趋势：一项全国性研究。
J Evid Based Med. 2019 Feb;12(1):22-28. doi: 10.1111/jebm.12318. Epub 2018 Nov 5.
引用本文的文献
1
Potential use of sodium glucose co-transporter 2 inhibitors during acute illness: a systematic review based on COVID-19.钠-葡萄糖共转运蛋白 2 抑制剂在急性疾病期间的潜在用途：基于 COVID-19 的系统评价。
Endocrine. 2024 Aug;85(2):660-675. doi: 10.1007/s12020-024-03758-8. Epub 2024 Mar 6.
2
The Role of Diabetes and Hyperglycemia on COVID-19 Infection Course-A Narrative Review.糖尿病和高血糖对新型冠状病毒肺炎感染病程的影响——一篇叙述性综述
Front Clin Diabetes Healthc. 2022 Mar 10;3:812134. doi: 10.3389/fcdhc.2022.812134. eCollection 2022.
3
COVID-19: Diabetes Perspective-Pathophysiology and Management.2019冠状病毒病：糖尿病视角——病理生理学与管理
Pathogens. 2023 Jan 25;12(2):184. doi: 10.3390/pathogens12020184.
4
Association of Glucose-Lowering Drugs With Outcomes in Patients With Diabetes Before Hospitalization for COVID-19: A Systematic Review and Network Meta-analysis.降糖药物与 COVID-19 住院前糖尿病患者结局的关联：系统评价和网络荟萃分析。
JAMA Netw Open. 2022 Dec 1;5(12):e2244652. doi: 10.1001/jamanetworkopen.2022.44652.
5
Knowledge, Attitudes, and Practices of COVID-19 Safety Measures Among Type 1 Diabetes Mellitus Patients at King Abdulaziz University Hospital: A Cross-Sectional Study.阿卜杜勒阿齐兹国王大学医院1型糖尿病患者对COVID-19安全措施的认知、态度和行为：一项横断面研究
Cureus. 2022 Aug 5;14(8):e27713. doi: 10.7759/cureus.27713. eCollection 2022 Aug.
6
COVID-19 and diabetes-Two giants colliding: From pathophysiology to management.COVID-19 与糖尿病——两大巨头的碰撞：从病理生理学到管理。
Front Endocrinol (Lausanne). 2022 Aug 19;13:974540. doi: 10.3389/fendo.2022.974540. eCollection 2022.
7
Association between use of novel glucose-lowering drugs and COVID-19 hospitalization and death in patients with type 2 diabetes: a nationwide registry analysis.新型降糖药物的使用与 2 型糖尿病患者 COVID-19 住院和死亡的关联：一项全国登记分析。
Eur Heart J Cardiovasc Pharmacother. 2022 Dec 15;9(1):10-17. doi: 10.1093/ehjcvp/pvac044.
8
Perceptions about the Management of Patients with DM2 and COVID-19 in the Hospital Care Setting.关于医院护理环境中2型糖尿病合并新冠肺炎患者管理的认知
J Clin Med. 2022 Aug 2;11(15):4507. doi: 10.3390/jcm11154507.
9
Screening of potential inhibitors of COVID-19 with repurposing approach via molecular docking.通过分子对接以重新利用的方法筛选新型冠状病毒肺炎的潜在抑制剂。
Netw Model Anal Health Inform Bioinform. 2022;11(1):11. doi: 10.1007/s13721-021-00341-3. Epub 2022 Feb 4.
10
Dipeptidyl peptidase-4 (DPP-IV) inhibitor was associated with mortality reduction in COVID-19 - A systematic review and meta-analysis.二肽基肽酶-4（DPP-4）抑制剂与 COVID-19 患者死亡率降低相关——一项系统评价和荟萃分析。
Prim Care Diabetes. 2022 Feb;16(1):162-167. doi: 10.1016/j.pcd.2021.12.008. Epub 2021 Dec 13.
本文引用的文献
1
COVID-19 and diabetes: Can DPP4 inhibition play a role?2019冠状病毒病与糖尿病：二肽基肽酶4抑制作用能否发挥作用？
Diabetes Res Clin Pract. 2020 Apr;162:108125. doi: 10.1016/j.diabres.2020.108125. Epub 2020 Mar 26.
2
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.COVID-19：建议检查羟氯喹预防感染和进展的效果。
J Antimicrob Chemother. 2020 Jul 1;75(7):1667-1670. doi: 10.1093/jac/dkaa114.
3
Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?高血压和糖尿病患者感染新型冠状病毒肺炎（COVID-19）的风险会增加吗？
Lancet Respir Med. 2020 Apr;8(4):e21. doi: 10.1016/S2213-2600(20)30116-8. Epub 2020 Mar 11.
4
Clinical Characteristics of Coronavirus Disease 2019 in China.《中国 2019 年冠状病毒病临床特征》
N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.
5
SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy.钠-葡萄糖协同转运蛋白2抑制剂作为糖尿病肾病的一种治疗选择
Int J Mol Sci. 2017 May 18;18(5):1083. doi: 10.3390/ijms18051083.
6
Activation of the GLP-1 Receptor by Liraglutide Increases ACE2 Expression, Reversing Right Ventricle Hypertrophy, and Improving the Production of SP-A and SP-B in the Lungs of Type 1 Diabetes Rats.利拉鲁肽激活胰高血糖素样肽-1受体可增加1型糖尿病大鼠肺组织中血管紧张素转换酶2（ACE2）的表达，逆转右心室肥厚，并改善肺表面活性蛋白A（SP-A）和肺表面活性蛋白B（SP-B）的产生。
Endocrinology. 2015 Oct;156(10):3559-69. doi: 10.1210/en.2014-1685. Epub 2015 Jul 21.
7
Insulin treatment attenuates renal ADAM17 and ACE2 shedding in diabetic Akita mice.胰岛素治疗可减轻糖尿病 Akita 小鼠肾脏 ADAM17 和 ACE2 的脱落。
Am J Physiol Renal Physiol. 2014 Mar 15;306(6):F629-39. doi: 10.1152/ajprenal.00516.2013. Epub 2014 Jan 22.
8
Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3-TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study.吡格列酮改善 2 型糖尿病患者的葡萄糖代谢，并调节骨骼肌 TIMP-3-TACE 二聚体：一项随机、双盲、安慰剂对照、机制研究。
Diabetologia. 2013 Oct;56(10):2153-63. doi: 10.1007/s00125-013-2976-z. Epub 2013 Jun 30.
Zotero 插件